recommended in 2011 by 50% of DHHS panel members, whereas the other 50% viewed treatment as optional. In 2012, ART was recommended for all HIV-infected individuals [6] .
In January 2010, the San Francisco Department of Public Health (SFDPH) adopted a policy to offer ART to all HIVinfected persons treated at public health facilities regardless of CD4 cell count [7] . This recommendation was based on the proven efficacy of ART at reducing HIV-and non-HIV-related morbidity and mortality as well as evidence of the harmful effects of persistent, elevated systemic inflammation in untreated individuals [8] . We measured trends in CD4 cell count at ART initiation during 2007-2011 to assess the extent to which national and local treatment recommendations were followed. We also measured the population characteristics and predictors of ART initiation at higher CD4 cell count with particular attention to possible socioeconomic and racial disparities in the timing of ART initiation.
METHODS

HIV Surveillance Activities
By law, persons with HIV infection are reported to the SFDPH. Laboratories are required to report all confirmed HIV-positive antibody, viral load, and CD4 test results. HIV case records are updated monthly with new CD4 and viral load test results. In addition, every 12-24 months, medical records of cases are reviewed at the San Francisco facilities where the patients are known to have received care to obtain new information on ART use. Vital status updates are obtained through monthly matches with local vital statistics and annual matches with the California State Death File, Social Security Death File, and the National Death Index. Annual evaluations of HIV surveillance find that completeness rates are consistently above 98% and that 95% of cases have been reported within 6 months of diagnosis [9] .
Study Populations and Data Analyses
The study population included San Francisco adult and adolescent residents (aged ≥13 years) who were diagnosed with HIV in San Francisco between 2007 and 2011 or diagnosed prior to 2007 and were alive as of 1 January 2007, and were not known to have initiated ART prior to 1 January 2007. Persons without any CD4 or viral load test during the study follow-up period were excluded. All data were reported to SFDPH as of 23 January 2013.
Initiation of ART Among Persons Newly Diagnosed With HIV Between 2007 and 2011
The CD4 count at HIV diagnosis was defined as the CD4 count closest to and within 6 months of HIV diagnosis. We used the Kaplan-Meier product limit method to estimate time between HIV diagnosis and ART initiation for each year among persons whose CD4 count at diagnosis was <200 cells/mm 3 ). Annual trends in the proportion of living patients who initiated ART were tested using generalized linear binomial regression.
To assess independent factors associated with ART initiation, we used a Poisson regression model that allowed us to estimate the effect of calendar year as well as nadir CD4, 2 time-dependent covariates of interest. The start of follow-up was 1 January 2007 for persons diagnosed before 2007 and was the date of HIV diagnosis for persons diagnosed on or after 1 January 2007. The end of follow-up was the date of ART initiation or the last censored date for persons not known to have started ART. Accordingly, follow-up time for each patient was first divided into annual intervals and then further subdivided each time a new nadir CD4 count category was reported; an event was assigned to the last interval for cases initiating ART. The log of the length of each interval was included as an offset in the model. All other predictors of interest were fixed, including gender, race/ethnicity, age at start of follow-up, risk group, and insurance at diagnosis. Robust standard errors were used [10] . We summarized adjusted covariate effects on the rate of ART initiation using incidence rate ratios.
All analyses were conducted using SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
There were 16 326 persons aged ≥13 years diagnosed with HIV by 31 December 2011 and alive between 2007 and 2011. We excluded 10 890 patients who were known to have started ART prior to 2007 and 995 patients who did not have a laboratory test during the study period. Of the 4441 patients included, 90% were male; 56% were white, 16% African American, and 18% Latino. Those aged 30-49 years accounted for 64% of the cases, and the 13-29 years and ≥50 years age groups were each 18% of cases. By risk group, most cases were men who have sex with men (MSM) (68%), followed by MSM injection drug users (IDUs) (17%), heterosexual IDUs (8%), and no identifiable risk (7%).
There were 2138 persons diagnosed with HIV between 2007 and 2011. The time from diagnosis to treatment decreased over time in persons diagnosed with a higher CD4 cell count b Nadir CD4 count reflects the lowest CD4 count during the year for living patients and in the year of ART initiation for those who started ART.
c Persons living with HIV at the end of each year who had at least 1 laboratory test during the year and who were not known to be on ART at the beginning of the year. A person may appear in different years and nadir CD4 count groups until the person started ART.
(Supplementary Figure 1) . Among newly diagnosed persons whose CD4 count at diagnosis was <200 cells/mm (Table 1) . There was a significant increase in the number and proportion of cases starting ART between 2007 and 2010 among persons whose nadir CD4 was between 351 and 500 cells/mm 3 (P < .0001) or >500 cells/ mm 3 (P < .0001).
Significantly higher rates of ART initiation were observed each year beginning in 2008 after adjustment for other factors ( Table 2 ). The rate of ART initiation in 2011 was 86% higher than the rate in 2007 (rate ratio [RR], 1.86; 95% confidence interval [CI], 1.5-2.2). Lower CD4 counts were strongly associated with initiating ART, particularly for persons whose nadir CD4 count was <200 cells/mm 3 relative to persons whose nadir CD4 count was >500 cells/mm 3 (RR, 10.33; 95% CI, 8.7-12.3).
Other demographic and risk factors independently associated with lower rates of ART initiation included African American race (RR, 0.74; 95% CI, .6-.9), MSM IDU (RR, 0.68; 95% CI, .6-.8), and age ≥50 years (RR, 0.77; 95% CI, .7-.9). in San Francisco is likely due to high levels of awareness, knowledge, and expertise in HIV research, treatment, and care. However, as expected, among persons whose CD4 count was <200 cells/mm 3 and therefore would have been advised to start treatment immediately, there was essentially no change in the time from diagnosis to the start of treatment or in the proportion initiating ART over the study period.
DISCUSSION
We observed important disparities with significantly lower rates of ART initiation among African Americans, older persons, and MSM IDUs. Many factors may hinder early ART initiation including late diagnosis, delays in care, and less optimal care. Social, lifestyle, and structural factors may serve as barriers to treatment for IDUs [11] . Treatment of non-HIVrelated medical conditions in older populations may take priority over or complicate initiation of ART [12] . The disproportionately lower rates of ART use among African Americans and IDUs in San Francisco are of particular concern because they have been evident for well over a decade, indicating that efforts to eliminate these disparities have not been successful [13] .
Our study has several limitations. Ascertainment of ART initiation is less complete for persons who were diagnosed or started ART in recent years because follow-up medical chart reviews may be incomplete. In addition, we may not be aware of all medical settings where patients received treatment and we were unable to access medical records at some private practices.
As a result, ART use is likely underestimated and, therefore, our methods provide conservative estimates of ART initiation in the study population. In addition, we were unable to calculate the person-time in the Poisson model if CD4 test results were missing or occurred after the end of follow-up and 10% of persons diagnosed during 2007-2011 were missing CD4 count at diagnosis and 8% of persons who were known to have started ART were missing CD4 count at ART initiation. Last, some cases diagnosed in recent years may not have been included because of reporting delays.
There are, however, notable strengths to our study. To our knowledge, SFDPH is the only health department in the United States that collects follow-up information regarding use of ART among persons reported with HIV. In support of our findings, recent studies have demonstrated increases in viral suppression among persons with HIV in San Francisco. An analysis of San Francisco HIV cases diagnosed between 2004 and 2010 found a significant reduction in time to viral suppression [14] . A study conducted at the San Francisco county hospital found that the rate of viral suppression dramatically increased after San Francisco's universal ART policy for patients with a CD4 count >500 cells/mm 3 [15] .
We conclude that ART uptake is increasing among HIV-infected persons in San Francisco and the time between diagnosis and ART initiation is decreasing among persons with higher CD4 cell counts. Racial and social disparities in early treatment during the study period are evident. SFDPH has developed new and expanded existing programs to facilitate timely entry into care and reentry for persons who have fallen out of care as one method to address care and treatment disparities. Continued monitoring of the SFDPH universal ART access policy using routinely collected surveillance data can help assess the extent to which these efforts have succeeded.
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